Navigation Links
Combination therapy improves AIDS-related lymphoma outcome

in Bremen, Germany, treated 72 HIV-patients with ARL divided into high-risk and standard-risk cohorts with combined CHOP and HAART to evaluate the safety and efficacy of the combined regimen.

The investigators found combined therapy improved survival rates for patients with ARL and standard level of risk to rates comparable to those in non-HIV patients with lymphoma treated with CHOP and superior to previously published rates achieved by CHOP alone. For standard-risk ARL patients 79 percent achieved complete remission, and after 47 months of follow-up and study's end, more than 50 percent of patients survived. Moreover, only 40 percent reported moderate drug toxicity. For high-risk ARL patients, only 29 percent achieved complete remission and median survival was only 7.2 months. Sixty-nine percent reported moderate toxicity.

"The present study showed that our risk-adapted strategy for concomitant administration of HAART with CHOP is effective and safe," the authors concluded.


'"/>

Source:John Wiley & Sons, Inc.


Page: 1 2

Related biology news :

1. Combination therapy boosts effectiveness of telomere-directed cancer cell death
2. Combination therapy leads to partial recovery from spinal cord injury in rats
3. Combination therapy with a monocloncal antibody and a vaccine leads to tumor rejection
4. Combination therapy shows promising results in patients with advanced lung cancer
5. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
6. Columbia research lifts major hurdle to gene therapy for cancer
7. Gene therapy converts dead bone graft to new, living tissue
8. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
9. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
10. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
11. New therapy for HIV/AIDS eliminates needles and excessive toxicity

Post Your Comments:
(Date:11/24/2009)...akened and flabby arteries from collapsing have be...tents are no longer needed -- once the arteries ar...y, doctors had no choice but to leave them in plac...ty,s Department of Biomedical Engineering has deve...ries drugs where they,re needed, then dissolves. ,...
(Date:11/24/2009)...rctica has long held secrets of the earth,s histor...ere has been very little information on the enviro...for millions of years. Now, a team of researchers ...unded to the tune of $10 million dollars by the Na...ottom of things literally. These scientists will ...
(Date:11/23/2009)...rch presents strong evidence that the "synergistic...affic-related pollution and indoor endotoxin cause...her exposure alone. , Environmental health sci...ge of Medicine have shown that children exposed to... indoor endotoxin during early life are six times ...
Breaking Biology News(10 mins):A coating for life 2LSU gets to the bottom of things -- in Antarctica 2Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2Vyvanse Capsules CII administration through 2 routes demonstrated similar pharmacokinetic profile 59967 1Vyvanse Capsules CII administration through 2 routes demonstrated similar pharmacokinetic profile 59967 2Vyvanse Capsules CII administration through 2 routes demonstrated similar pharmacokinetic profile 59967 3Rotavirus Vaccine Cutting Infection Rates Among Kids 59964 1Rotavirus Vaccine Cutting Infection Rates Among Kids 59964 2Syphilis survey reveals need for accurate testing for early infection 59960 1
...ing environmental study to be published in a prest...y atmospheric emissions will end up in fish in as ...ity of Alberta in Edmonton, Canada, played a key r..., The study concludes that if mercury emissions f...ctivities were to be cut immediately, the amount s...
...CScientists are working to produce cheap, sustaina...gy researchers like California Institute of Techno...materials that mimic the architecture of grass and...gy. , A new podcast looks at how Dr. Lewis and h...nanoparticles into simple, inexpensive everyday pr...
...earchers led by Fei Hu, assistant professor of com...logy, is working to advance the integration of rad... as RFID, into cardiac sensor networks, a new wire...m will also work to enhance the security of the sy...ssibility of identity theft and cyber-terrorism. T...
Other Biology News:New research seeks to enhance quality and security of wireless telemedicine 2
(Date:11/23/2009)...3/PRNewswire/--Frost&Sullivan,theGrowthPartner...tingleadershipandinnovationThursday,November19,200...theldinSanAntonio,Texas. ,, (Logo: http://www.n...eHealthcareInnovationAwardsaregiventocompaniesthat...nagementofhealthcare.Suchcompanieshaveshownsuccess...
(Date:11/23/2009)...re-FirstCall/--CornerstoneTherapeuticsInc.(Nasdaq:...quiring,developingandcommercializingsignificantpro...odayannouncedthatCraigA.Collard,PresidentandChiefE...atthe21stAnnualPiperJaffrayHealthCareConferenceat3...eHotelinNewYorkCity. ,, Aliveaudioandarchivedwe...
(Date:11/20/2009)...ies have an opportunity to take the lead in two sm...iversity of Valencia (UV), working together with t... fabric of the Spanish biotechnology industry. The...rs have more clout than those in English-speaking ...d plants has been overlooked by the leading countr...
(Date:11/20/2009)...ewswire-FirstCall/ -- Dendreon Corporation (Nasdaq...rug Administration (FDA) provided written acknowle...se Application (BLA) for PROVENGE® (sipuleuce... a Prescription Drug User Fee Act (PDUFA) date of ...reon,s amended BLA. Dendreon is seeking licensure...
Breaking Biology Technology:Excellence in Healthcare Innovation Recognized by Frost & Sullivan 2Excellence in Healthcare Innovation Recognized by Frost & Sullivan 3Cornerstone Therapeutics to Present at the 21st Annual Piper Jaffray Health Care Conference 2Spanish biotechnology should focus on food and plant sectors to be more competitive 2Dendreon Receives FDA Acknowledgement of Complete Response 2Dendreon Receives FDA Acknowledgement of Complete Response 3
...l 25 CV Therapeutics,Inc. (Nasdaq: CVTX ) today ...nded March 31, 2008., For the quarter ended March...9 million, or $0.53 per share. This compares to a ... the prior quarter ended December 31, 2007,and $55...er in 2007., For the quarter ended March 31, 2008...
...ntists and Collaborators Publish Study in Science,...bH, the,leading developer of RAFT intervention the...per in Science demonstrating a potential novel str...and other diseases by targeting,discrete sub-compa...nducted,by JADO scientists together with several a...
...lif., April 24 ,Exelixis, Inc. (Nasdaq: EXEL ) an...t and chief executive officer of Exelixis, will pr...ugged Conference at 3:40 p.m. ET/12:40,p.m. PT on ...s updates to,the company,s development pipeline an...ebcast and may be accessed in the Event,Calendar p...
Other Biology Technology:CV Therapeutics Reports 2008 First Quarter Financial Results 2CV Therapeutics Reports 2008 First Quarter Financial Results 3CV Therapeutics Reports 2008 First Quarter Financial Results 4CV Therapeutics Reports 2008 First Quarter Financial Results 5Novel Approach to Treat Alzheimer's and Other Diseases Offered by Targeting Cell Membrane RAFTS 2Novel Approach to Treat Alzheimer's and Other Diseases Offered by Targeting Cell Membrane RAFTS 3Novel Approach to Treat Alzheimer's and Other Diseases Offered by Targeting Cell Membrane RAFTS 4
Sheep Anti-Salmonella Thomasville Polyclonal Antibody, Unconjugated from Abcam
Mouse Anti-Drosophila Melanogaster Achaete protein Monoclonal Antibody, Unconjugated from Developmental Studies Hybridoma Bank
Rabbit Anti-OCT6 Polyclonal Antibody, Unconjugated from Abcam
...rk, Super-Small! Capture high-resolution chemilum...oc-It Imaging System. High-sensitivity camera is c...ound noise and wide dynamic range for high quality...cabinet provides optimum conditions for chemilumin...
Biology Products: